B
XENE icon

Braidwell’s Xenon Pharmaceuticals XENE Stock Holding History

Braidwell’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.3M Sell
1,131,452
-207,000
-15% -$11.5M 2.53% 9
2026
Q1 		$77.8M Sell
1,338,452
-486,624
-27% -$22.4M 2.6% 8
2025
Q4 		$81.8M Sell
1,825,076
-1,779,953
-49% -$74.8M 2.62% 9
2025
Q3 		$145M Hold
3,605,029
– – 4.29% 4
2025
Q2 		$113M Buy
3,605,029
+895,154
+33% +$29.2M 3.86% 5
2025
Q1 		$90.9M Sell
2,709,875
-204,089
-7% -$7.75M 3.2% 7
2024
Q4 		$114M Buy
2,913,964
+206,709
+8% +$8.55M 3.39% 6
2024
Q3 		$107M Buy
2,707,255
+146,682
+6% +$5.91M 3.02% 6
2024
Q2 		$99.8M Buy
2,560,573
+1,252,562
+96% +$50.1M 3.13% 7
2024
Q1 		$56.3M Sell
1,308,011
-339,300
-21% -$15.6M 1.81% 19
2023
Q4 		$75.9M Sell
1,647,311
-456,085
-22% -$16.1M 2.79% 8
2023
Q3 		$71.9M Buy
2,103,396
+275,043
+15% +$10.3M 2.27% 10
2023
Q2 		$70.4M Sell
1,828,353
-308,757
-14% -$12.3M 2.3% 13
2023
Q1 		$76.5M Buy
2,137,110
+589,000
+38% +$21.8M 2.52% 11
2022
Q4 		$61M Buy
+1,548,110
New +$56.4M 2.05% 14

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Braidwell's XENE Position: Q2 2026 in Review

Braidwell reduced its Xenon Pharmaceuticals (XENE) stake by 15% in Q2 2026, selling an estimated $11.5M and leaving 1,131,452 shares worth $68.3M. The position accounts for 2.53% of the portfolio, ranked #9.

Braidwell first reported a position in XENE in Q4 2022 and has held it in 15 quarters since. The position peaked at $145M in Q3 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Braidwell held 1,131,452 shares of Xenon Pharmaceuticals worth $68.3M as of Q2 2026.
  • Braidwell sold 207,000 Xenon Pharmaceuticals shares in Q2 2026, an estimated $11.5M.
  • Xenon Pharmaceuticals made up 2.53% of Braidwell's portfolio in Q2 2026, its #9 holding.
  • Braidwell first reported a position in Xenon Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Braidwell's Xenon Pharmaceuticals position peaked at $145M in Q3 2025.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.